CATX vs CBIO

Perspective Therapeutics, Inc. vs Crescent Biopharma, Inc. — Valuation Comparison 2026

CATX

Pharmaceutical Preparations
Perspective Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.94
Last close
Models
9/13
Active
VS

CBIO

Pharmaceutical Preparations
Crescent Biopharma, Inc.
Quality
5.3
out of 10
Value Trap
12
SAFE
Price
$20.65
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CATX Fair ValueCATX Upside CBIO Fair ValueCBIO Upside
Bayesian DCF Intrinsic $1.23 -68.7% $8.25 -60.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.05 -22.5% $4.01 -80.6%
Dynamic NAV Asset-Based $2.06 -47.8% $8.97 -56.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CATX vs CBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CATX vs CBIO — Which Stock Is More Undervalued?

CBIO scores higher with a 5.3/10 quality rating vs CATX's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Perspective Therapeutics, Inc. (CATX) and Crescent Biopharma, Inc. (CBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CATX currently trades at $3.94 with a QOC of 4.6/10, while CBIO trades at $20.65 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).